Jul. 1 at 8:22 PM
$EYPT The issue is not the phase 3 results. Yes, it is reasonable to expect those to be fine. Yes,
$EYPT used a sham in the studies which is against the recommendation of the FDA. I think that probably works out OK with a minor slap on the wrist.
The problem is that the study designs of
$OCUL give them a big advantage. I am not saying it is a better product. Yet,
$OCUL having a 1 year FDA durability label and superiority data will have a huge impact on sales.
